Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3006710 | 0.88 | OPRL1 (0.47) | KCNH2OPRL1POLBCCR3 | |
| SCHEMBL3018645 | 0.74 | OPRL1 (0.49) | OPRL1POLBCCR3 | |
| SCHEMBL15580470 | 0.74 | SIGMAR1 (0.42) | KCNH2 | |
| SCHEMBL3015736 | 0.73 | OPRL1 (0.49) | OPRL1POLBCCR3 | |
| SCHEMBL3026822 | 0.71 | OPRL1 (0.47) | OPRL1POLBCCR3 | |
| SCHEMBL8107817 | 0.71 | OPRL1 (0.47) | OPRL1POLBCCR3 | |
| SCHEMBL25355733 | 0.71 | OPRL1 (0.57) | OPRL1POLBCCR3 | |
| SCHEMBL31283053 | 0.70 | OPRL1 (0.46) | OPRL1POLBCCR3 | |
| SCHEMBL2970071 | 0.69 | CHRM4 (0.64) | OPRL1POLBCCR3 | |
| SCHEMBL31028218 | 0.69 | CHRM4 (0.64) | OPRL1POLBCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144915-B1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | ESTEVE LABOR DR (ES) | 2014-03-19 | — | — | EP | disclosed |
| EP-2144915-B1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | ESTEVE LABOR DR (ES) | 2014-03-19 | — | — | EP | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| WO-2008125349-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-23 | — | — | WO | disclosed |
| EP-1982987-A1 | Spiro-pyrano-pyrazole derivatives | Laboratorios del Dr. Esteve S.A. (ES) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | SIGMAR1, TMEM97, OPRD1 | KCNH2 645/4885OPRL1 43/4885POLB 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.